NCT00333138 - Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis | Biotech Hunter

Enrollment

281

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Multiple Sclerosis

Interventions

DRUG

FTY720

FTY720 capsule was taken orally once a day

DRUG

Placebo

Placebo 1.25 mg capsule was given once daily

Trial Locations (26)

Novartis Investigational site, Montreal

Novartis Investigational site, Ottawa

Novartis Investigational site, Toronto

Novartis Investigational site, Vancouver

Novartis Investigational site, Copenhagen

Novartis Investigational site, Helsinki

Novartis Investigational site, Turku

Novartis Investigational site, Lille

Novartis Investigational site, Marseille

Novartis Investigational site, Schwendi

Novartis Investigational site, Würzburg

Novartis Investigational site, Gallarate

Novartis Investigational site, Genova

Novartis Investigational site, Milan

Novartis Investigational site, Roma

Novartis Investigational site, Warsaw

Novartis Investigational site, Coimbra

Novartis Investigational site, Lisbon

Novartis Investigational site, Barcelona

Novartis Investigational site, Madrid

Novartis Investigational site, Málaga

Novartis Investigational site, Seville

Novartis Investigational site, Valencia

Novartis Investigational site, Basel

Novartis Investigational site, Zurich

Novartis Investigational site, Newcastle upon Tyne